Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Friday Jul 26, 2024
Friday Jul 26, 2024
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of leading experts discuss the latest evidence and clinical implications of recently approved treatments for relapsed/refractory follicular lymphoma (R/R FL), the importance of shared decision-making in treatment selection in the era of BsAb and CAR T-cell therapies, and the key considerations for treatment sequencing.
The experts
- Dr Matthew Lunning, University of Nebraska, Omaha, NE, USA,
- Professor Charalambos Andreadis, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA,
- Dr Tara Graff, Mission Cancer and Blood, Des Moines, IA, USA.
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Bristol Myers Squibb and is jointly provided by USF Health and touchIME.
For further information visit: https://touchoncologyime.org/evolving-treatment-paradigm-relapsed-refractory-follicular-lymphoma
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.